BioAge discontinues mid-stage trial of obesity drug-February 2024-www.financetom.com

BioAge discontinues mid-stage trial of obesity drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BioAge discontinues mid-stage trial of obesity drug

Dec 6, 2024 1:55 PM

Dec 6 (Reuters) - BioAge Labs ( BIOA ) said on Friday it

is discontinuing its mid-stage trial studying its experimental

drug as a monotherapy and in combination with Eli Lilly's ( LLY )

tirzepatide for the treatment of obesity.

Previous page： --Boeing Retaliated Against Workers Who Raised Concerns, Union Says Next page： Exclusive-EU concerned about KKR, Telecom Italia deal impact on wholesale competition, sources say

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Boeing Retaliated Against Workers Who Raised Concerns, Union Says

Apr 23, 2024

01:39 PM EDT, 04/23/2024 (MT Newswires) -- Price: 168.91, Change: -1.57, Percent Change: -0.92 ...

Exclusive-EU concerned about KKR, Telecom Italia deal impact on wholesale competition, sources say

Apr 23, 2024

BRUSSELS/ROME (Reuters) - European Union antitrust regulators are asking rivals and customers whether proposed acquisition of Telecom Italia's (TIM) fixed-line access network by U.S. investment firm KKR could hamper Italy's wholesale market, people familiar with the matter said on Tuesday. Such regulatory worries could lead to a lengthy investigation of the deal and put pressure on KKR to offer significant...

ADM CFO to resign as company faces US government investigation

Apr 23, 2024

(Reuters) - Grain trader Archer-Daniels-Midland said on Monday that Chief Financial Officer Vikram Luthar will resign from his role effective Sept. 30. Luthar is the highest-level executive to leave the firm since it disclosed accounting issues within its Nutrition division that later triggered two government investigations and forced it to revise six years of financial data. ADM had put Luthar...

What's Going On With Freeport-McMoRan Shares Today?

Apr 23, 2024

Freeport-McMoRan Inc. ( FCX ) shares are trading lower after the company reported first-quarter FY24 results. Revenue stood at $6.32 billion, beating the consensus of $5.66 billion. Adjusted EPS was $0.32, beating the consensus of $0.27. Copper sales (excluding purchases) totaled 1.1 billion pounds, an increase of 33% Y/Y, led by higher mining and milling rates and ore grades at PT-FI. The average realized...